Hormone receptor expression in uterine sarcomas: Prognostic and therapeutic roles

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 466-471

  Ioffe, Y J ^a   Li, A J ^a   Walsh, C S ^a   Karlan, B Y ^a   Leuchter, R ^a   Forscher, C ^a   Cass, I ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Estrogen receptor; Uterine sarcoma

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN CITRATE;

AGE DISTRIBUTION; ARTICLE; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERUS SARCOMA;

ADENOSARCOMA; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; CARCINOSARCOMA; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SARCOMA; SARCOMA, ENDOMETRIAL STROMAL; UTERINE NEOPLASMS;

EID: 70350567746     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.014     Document Type: Article

References (39)

1. Curtin J.P., Kavanagh J.J., Fox H., et al. Corpus: mesenchymal tumors. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and Practice of Gynecologic Oncology, 2d ed. (1997), Lippincott, Philadelphia 897
2. Zaloudek C., and Hendrickson M.R. Mesenchymal tumors of the uterus. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract (2004), Springer-Verlag, Inc., New York 578-583
3. Marchese M.J., Liskow A.S., Crum C.P., et al. Uterine sarcomas: a clinicopathologic study. 1965-1981. Gynecol. Oncol. 18 (1984) 299-312
4. Nordal R.R., and Thoresen S.O. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur. J. Cancer 33 6 (1997) 907-911
5. Aaro L.A., Symmonds R.E., and Dockerty M.B. Sarcoma of the uterus: a clinical and pathological study of 177 cases. Am. J. Obstet. Gynecol. 94 (1966) 101-109
6. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group Study. Cancer 71 (1993) 1702-1709
7. Hannigan E.V., and Gomez L.G. Uterine leiomyosarcoma. Am. J. Obstet. Gynecol. 134 (1979) 557-564
8. Pautier P., Genestie C., Rey a., et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 6 (2000) 1425-1431
9. Kitchner H.C., and Trimble E.L. Endometrial cancer state of the science meeting. Int. J. Gynecol. Cancer 19 1 (2009) 134-140
10. Gadducci A., Cosio S., Romanini A., et al. The management of uterine sarcomas: a debated clinical challenge. Crit. Rev. Oncol. Hematol. 65 (2008) 129-142
11. Homesley H.D., Filiaci V., Markman M., et al. Phase III Trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group study. J. Clin. Oncol. 25 5 (2007) 526-531
12. Hensley M.L., Blessing J.A., and DeGeest K. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol. Oncol. 109 (2008) 323-328
13. Reich O., and Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr. Opin. Oncol. 19 4 (2007) 347-352
14. Garrett A., and Quinn M.A. Hormonal therapies and gynaecological cancers. Best Pract. Res. Clin. Obstet. Gynaecol. 22 2 (2008) 407-421
15. Kitaoka Y., Kitawaki J., Koshiba S., et al. Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcoma: correlation with clinical parameters. J Steroid Biochem. Molecular Biol. 88 (2004) 183-189
16. Bodner K., Bodner-Adler B., Kimberger O., et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 23 1B (2003) 729-732
17. Zhai Y.L., Kobayashi Y., Mori A., et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int. J. Gynecol. Pathol. 18 1 (1999) 20-28
18. Wade K., Quinn M.A., Hammond I., et al. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol. Oncol. 39 3 (1990) 364-367
19. Sutton G.P., Stehman F.B., Michael H., et al. Estrogen and progesterone receptors in uterine sarcomas. Obstet. Gynecol. 68 5 (1986) 709-714
20. Reich O., Regauer S., Urdl W., et al. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br. J. Cancer 82 5 (2000) 1030-1034
21. Kyndi M., Sorensen F.B., Knudsen H., et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 26 9 (2008) 1419-1426
22. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin. Chem. 51 3 (2005) 494-503
23. Akhan S.E., Yavuz E., Tecer A., et al. The expression of Ki-67, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas: a clinicopathologic study. Gynecol. Oncol. 99 (2005) 36-42
24. Bodner K., Bodner-Adler B., Kimberger O., et al. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril. 81 4 (2004) 1062-1066
25. Raspollini M.R., Amunni A., Villanucci V., et al. Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome. J. Chemother. 15 (2003) 596-602
26. Ma S.K., Zhang H.T., Wu L.Y., et al. Treatment and prognosis of low-grade malignant endometrial stromal sarcoma. Chin. J. Oncol. 29 1 (2007) 74-78
27. Gadduci A., Sartori E., Landoni F., et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur. J. Gynaecol. Oncol. 23 4 (2002) 295-299
28. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 3 (2000) 205-216
29. Chu M.C., Mor G., Lim C., et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol. Oncol. 90 (2003) 170-176
30. Tavassoli F.A., and Schnitt S.J. Pathology of the Breast (1992), Elsevier, Oxford
31. Kun Y., How L.C., Hoon T.P., et al. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of ERBB2 receptor. Hum. Mol. Genet. 12 24 (2003) 3245-3258
32. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post-menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21 (2003) 2101-2119
33. Baum M., Budzar A.U., Cuzick J., et al. ATAC trialists' group: anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
34. Thurlimann B., Keshaviah A., Coates A.S., et al. Breast International Group (BIG) 1-98 collaborative group: a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
35. Brechot J.M., Kamboucher M., Brauner M.D., et al. Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy. Rev. Mal. Respir. 24 1 (2007) 69-72
36. Pink D., Lindner T., Mrozek A., et al. Harm of benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma : a single center experience with 10 cases and review of literature. Gynecol. Oncol. 101 3 (2006) 464-469
37. Koivisto-Korander R., Leminen A., and Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet. Gynecol. 109 2 (2007) 512-514
38. Hardman M.P., Roman J.J., Burnett A.F., et al. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet. Gynecol. 110 (2007) 518-520
39. Lo C.A., Huang S.C., Ho C.L., et al. Discordant responses to progestin in a patient with uterine low-grade smooth-muscle tumors metastatic to the lung. J. Obstet. Gynaecol. Res. 31 5 (2005) 394-398